Plain-English translation of NCT07362446 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help protect your heart after a sudden, life-threatening heart attack (called STEMI). You would receive the medication as an intravenous infusion for 6 hours while you're getting emergency treatment to restore blood flow to your heart. Researchers want to learn whether this treatment can improve your heart health and recovery.
When blood flow to the heart is suddenly blocked and then restored during emergency surgery, the heart can suffer additional injury. This medication is being tested to see if it can reduce that secondary damage and improve long-term outcomes for heart attack patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or a placebo (a dummy infusion with no medicine) as a 6-hour intravenous infusion during your emergency heart attack treatment. You'll stay in the hospital for standard care, and researchers will monitor your heart health with blood tests, heart imaging, and electrocardiograms. You'll have one follow-up visit to the hospital on day 30, plus phone check-ins, for a total study duration of about 30 days.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia